FibroBiologics Stock Forecast
NASDAQ: FBLGHealth CareBiotechnology: Pharmaceutical PreparationsUSD
Market open · Delayed 15 min · as of Oct 9, 12:33 PM ET
FBLG analyst consensus
Consensus (2 analysts)
none
Avg. price target
$12.50+968.38%
- Strong buy 0
- Buy 1
- Hold 1
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
What analysts say
According to 2 Wall Street analysts covering FibroBiologics (2026-10-09), 1 rate the stock a buy or strong buy, 1 rate it a hold and 0 rate it a sell or strong sell, for a consensus rating of "none". The average 12-month price target is $12.50, with a high estimate of $19.00 and a low estimate of $6.00. The average target implies upside of 968.4% from the current price of $1.17.
The spread between the highest and lowest targets is 216.7%, a wide range that reflects significant disagreement among analysts. Price targets and ratings are the opinions of third-party analysts, not MetaCap. They are frequently revised and have a mixed track record, so treat them as one input among many for FBLG.
Summary generated from market data by MetaCap's automated system. Methodology
Rating distribution
| Rating | Analysts | Share |
|---|---|---|
| Strong buy | 0 | 0% |
| Buy | 1 | 50% |
| Hold | 1 | 50% |
| Sell | 0 | 0% |
| Strong sell | 0 | 0% |
Ratings as of 2026-10-09.
Price target scenarios
| Target | Price | vs. current |
|---|---|---|
| Low target | $6.00 | +412.82% |
| Average target | $12.50 | +968.38% |
| High target | $19.00 | +1523.93% |